News | April 07, 2008

Bi-Atrial Lesion Pattern Produces Positive Positive Results in Afib Patients

April 8, 2008 - Atrial fibrillation demonstrated that a port access, paracardioscopic Ex-Maze procedure produced favorable outcomes and allowed patients to discontinue antiarrhythmic drugs, according to interim results from a study presented by Andy C. Kiser, M.D., at the American College of Cardiology meeting in Chicago, IL.

Epicardial lesions to complete the bi-atrial pattern were created in all patients by coagulating cardiac tissue using the nContact Surgical VisiTrax device.

The 37 patients reported in the study had an average age of 61 years, a mean duration of atrial fibrillation of 7.4 years, and a mean left atrial size of 5.7 cm. Seventy-eight percent of the patients had long-standing persistent atrial fibrillation. Analysis of three-month interim outcomes demonstrated normal sinus rhythm in 17/20 (85 percent) patients. For those patients who had reached six months, 7/7 (100 percent) patients experienced normal sinus rhythm without antiarrhythmic drugs.

"This is a truly minimally invasive approach that treats both the left and right atrium without the use of cardiopulmonary bypass,"? stated Dr. Kiser. "These interim closed-chest results are very promising, particularly, when intra-operative metrics, including spontaneous conversion to normal sinus rhythm and confirmed exit block, are met."

For more information: www.Ex-Maze.com and www.ncontactsurgical.com


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now